Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 108

1.

Unique Neoantigens Arise from Somatic Mutations in Patients with Gastrointestinal Cancers.

Parkhurst MR, Robbins PF, Tran E, Prickett TD, Gartner JJ, Jia L, Ivey G, Li YF, El-Gamil M, Lalani A, Crystal JS, Sachs A, Groh E, Ray S, Ngo LT, Kivitz S, Pasetto A, Yossef R, Lowery FJ, Goff SL, Lo W, Cafri G, Deniger DC, Malekzadeh P, Ahmadzadeh M, Wunderlich JR, Somerville RPT, Rosenberg SA.

Cancer Discov. 2019 Aug;9(8):1022-1035. doi: 10.1158/2159-8290.CD-18-1494. Epub 2019 Jun 4.

PMID:
31164343
2.

A Phase II Study of Tumor-infiltrating Lymphocyte Therapy for Human Papillomavirus-associated Epithelial Cancers.

Stevanović S, Helman SR, Wunderlich JR, Langhan MM, Doran SL, Kwong MLM, Somerville RPT, Klebanoff CA, Kammula US, Sherry RM, Yang JC, Rosenberg SA, Hinrichs CS.

Clin Cancer Res. 2019 Mar 1;25(5):1486-1493. doi: 10.1158/1078-0432.CCR-18-2722. Epub 2018 Dec 5.

3.

T-cell Responses to TP53 "Hotspot" Mutations and Unique Neoantigens Expressed by Human Ovarian Cancers.

Deniger DC, Pasetto A, Robbins PF, Gartner JJ, Prickett TD, Paria BC, Malekzadeh P, Jia L, Yossef R, Langhan MM, Wunderlich JR, Danforth DN, Somerville RPT, Rosenberg SA.

Clin Cancer Res. 2018 Nov 15;24(22):5562-5573. doi: 10.1158/1078-0432.CCR-18-0573. Epub 2018 May 31.

PMID:
29853601
4.

Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: a single-centre, two-stage, single-arm, phase 2 study.

Chandran SS, Somerville RPT, Yang JC, Sherry RM, Klebanoff CA, Goff SL, Wunderlich JR, Danforth DN, Zlott D, Paria BC, Sabesan AC, Srivastava AK, Xi L, Pham TH, Raffeld M, White DE, Toomey MA, Rosenberg SA, Kammula US.

Lancet Oncol. 2017 Jun;18(6):792-802. doi: 10.1016/S1470-2045(17)30251-6. Epub 2017 Apr 7.

5.

Characterization of an Immunogenic Mutation in a Patient with Metastatic Triple-Negative Breast Cancer.

Assadipour Y, Zacharakis N, Crystal JS, Prickett TD, Gartner JJ, Somerville RPT, Xu H, Black MA, Jia L, Chinnasamy H, Kriley I, Lu L, Wunderlich JR, Zheng Z, Lu YC, Robbins PF, Rosenberg SA, Goff SL, Feldman SA.

Clin Cancer Res. 2017 Aug 1;23(15):4347-4353. doi: 10.1158/1078-0432.CCR-16-1423. Epub 2017 Apr 4.

6.

A Pilot Trial of the Combination of Vemurafenib with Adoptive Cell Therapy in Patients with Metastatic Melanoma.

Deniger DC, Kwong ML, Pasetto A, Dudley ME, Wunderlich JR, Langhan MM, Lee CR, Rosenberg SA.

Clin Cancer Res. 2017 Jan 15;23(2):351-362. doi: 10.1158/1078-0432.CCR-16-0906. Epub 2016 Oct 7.

7.

Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients With Metastatic Melanoma.

Goff SL, Dudley ME, Citrin DE, Somerville RP, Wunderlich JR, Danforth DN, Zlott DA, Yang JC, Sherry RM, Kammula US, Klebanoff CA, Hughes MS, Restifo NP, Langhan MM, Shelton TE, Lu L, Kwong ML, Ilyas S, Klemen ND, Payabyab EC, Morton KE, Toomey MA, Steinberg SM, White DE, Rosenberg SA.

J Clin Oncol. 2016 Jul 10;34(20):2389-97. doi: 10.1200/JCO.2016.66.7220. Epub 2016 May 23.

8.

Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients.

Gros A, Parkhurst MR, Tran E, Pasetto A, Robbins PF, Ilyas S, Prickett TD, Gartner JJ, Crystal JS, Roberts IM, Trebska-McGowan K, Wunderlich JR, Yang JC, Rosenberg SA.

Nat Med. 2016 Apr;22(4):433-8. doi: 10.1038/nm.4051. Epub 2016 Feb 22.

PMID:
26901407
9.

Identification of an Immunogenic Subset of Metastatic Uveal Melanoma.

Rothermel LD, Sabesan AC, Stephens DJ, Chandran SS, Paria BC, Srivastava AK, Somerville R, Wunderlich JR, Lee CC, Xi L, Pham TH, Raffeld M, Jailwala P, Kasoji M, Kammula US.

Clin Cancer Res. 2016 May 1;22(9):2237-49. doi: 10.1158/1078-0432.CCR-15-2294. Epub 2015 Dec 28.

10.

Immunogenicity of somatic mutations in human gastrointestinal cancers.

Tran E, Ahmadzadeh M, Lu YC, Gros A, Turcotte S, Robbins PF, Gartner JJ, Zheng Z, Li YF, Ray S, Wunderlich JR, Somerville RP, Rosenberg SA.

Science. 2015 Dec 11;350(6266):1387-90. doi: 10.1126/science.aad1253. Epub 2015 Oct 29.

11.

Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells.

Stevanović S, Draper LM, Langhan MM, Campbell TE, Kwong ML, Wunderlich JR, Dudley ME, Yang JC, Sherry RM, Kammula US, Restifo NP, Rosenberg SA, Hinrichs CS.

J Clin Oncol. 2015 May 10;33(14):1543-50. doi: 10.1200/JCO.2014.58.9093. Epub 2015 Mar 30.

12.

A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response.

Robbins PF, Kassim SH, Tran TL, Crystal JS, Morgan RA, Feldman SA, Yang JC, Dudley ME, Wunderlich JR, Sherry RM, Kammula US, Hughes MS, Restifo NP, Raffeld M, Lee CC, Li YF, El-Gamil M, Rosenberg SA.

Clin Cancer Res. 2015 Mar 1;21(5):1019-27. doi: 10.1158/1078-0432.CCR-14-2708. Epub 2014 Dec 23.

13.

Persistence of CTL clones targeting melanocyte differentiation antigens was insufficient to mediate significant melanoma regression in humans.

Chandran SS, Paria BC, Srivastava AK, Rothermel LD, Stephens DJ, Dudley ME, Somerville R, Wunderlich JR, Sherry RM, Yang JC, Rosenberg SA, Kammula US.

Clin Cancer Res. 2015 Feb 1;21(3):534-43. doi: 10.1158/1078-0432.CCR-14-2208. Epub 2014 Nov 25.

14.

Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer.

Tran E, Turcotte S, Gros A, Robbins PF, Lu YC, Dudley ME, Wunderlich JR, Somerville RP, Hogan K, Hinrichs CS, Parkhurst MR, Yang JC, Rosenberg SA.

Science. 2014 May 9;344(6184):641-5. doi: 10.1126/science.1251102.

15.

PD-1 identifies the patient-specific CD8⁺ tumor-reactive repertoire infiltrating human tumors.

Gros A, Robbins PF, Yao X, Li YF, Turcotte S, Tran E, Wunderlich JR, Mixon A, Farid S, Dudley ME, Hanada K, Almeida JR, Darko S, Douek DC, Yang JC, Rosenberg SA.

J Clin Invest. 2014 May;124(5):2246-59. doi: 10.1172/JCI73639. Epub 2014 Mar 25.

16.

Human melanoma metastases demonstrate nonstochastic site-specific antigen heterogeneity that correlates with T-cell infiltration.

Bartlett EK, Fetsch PA, Filie AC, Abati A, Steinberg SM, Wunderlich JR, White DE, Stephens DJ, Marincola FM, Rosenberg SA, Kammula US.

Clin Cancer Res. 2014 May 15;20(10):2607-2616. doi: 10.1158/1078-0432.CCR-13-2690. Epub 2014 Mar 19.

17.

Longitudinal study of recurrent metastatic melanoma cell lines underscores the individuality of cancer biology.

Pos Z, Spivey TL, Liu H, Sommariva M, Chen J, Wunderlich JR, Parisi G, Tomei S, Ayotte BD, Stroncek DF, Malek JA, Robbins PF, Rivoltini L, Maio M, Chouchane L, Wang E, Marincola FM.

J Invest Dermatol. 2014 May;134(5):1389-1396. doi: 10.1038/jid.2013.495. Epub 2013 Nov 22.

18.

Tumor-reactive CD8+ T cells in metastatic gastrointestinal cancer refractory to chemotherapy.

Turcotte S, Gros A, Tran E, Lee CC, Wunderlich JR, Robbins PF, Rosenberg SA.

Clin Cancer Res. 2014 Jan 15;20(2):331-43. doi: 10.1158/1078-0432.CCR-13-1736. Epub 2013 Nov 11.

19.

Gene expression profiling using nanostring digital RNA counting to identify potential target antigens for melanoma immunotherapy.

Beard RE, Abate-Daga D, Rosati SF, Zheng Z, Wunderlich JR, Rosenberg SA, Morgan RA.

Clin Cancer Res. 2013 Sep 15;19(18):4941-50. doi: 10.1158/1078-0432.CCR-13-1253. Epub 2013 Sep 10.

20.

Phenotype and function of T cells infiltrating visceral metastases from gastrointestinal cancers and melanoma: implications for adoptive cell transfer therapy.

Turcotte S, Gros A, Hogan K, Tran E, Hinrichs CS, Wunderlich JR, Dudley ME, Rosenberg SA.

J Immunol. 2013 Sep 1;191(5):2217-25. doi: 10.4049/jimmunol.1300538. Epub 2013 Jul 31.

21.

Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma.

Dudley ME, Gross CA, Somerville RP, Hong Y, Schaub NP, Rosati SF, White DE, Nathan D, Restifo NP, Steinberg SM, Wunderlich JR, Kammula US, Sherry RM, Yang JC, Phan GQ, Hughes MS, Laurencot CM, Rosenberg SA.

J Clin Oncol. 2013 Jun 10;31(17):2152-9. doi: 10.1200/JCO.2012.46.6441. Epub 2013 May 6.

22.

Myeloid cells obtained from the blood but not from the tumor can suppress T-cell proliferation in patients with melanoma.

Gros A, Turcotte S, Wunderlich JR, Ahmadzadeh M, Dudley ME, Rosenberg SA.

Clin Cancer Res. 2012 Oct 1;18(19):5212-23. doi: 10.1158/1078-0432.CCR-12-1108. Epub 2012 Jul 26.

23.

Minimally invasive liver resection to obtain tumor-infiltrating lymphocytes for adoptive cell therapy in patients with metastatic melanoma.

Alvarez-Downing MM, Inchauste SM, Dudley ME, White DE, Wunderlich JR, Rosenberg SA, Kammula US.

World J Surg Oncol. 2012 Jun 22;10:113. doi: 10.1186/1477-7819-10-113.

24.

Tumor-specific CD4+ melanoma tumor-infiltrating lymphocytes.

Friedman KM, Prieto PA, Devillier LE, Gross CA, Yang JC, Wunderlich JR, Rosenberg SA, Dudley ME.

J Immunother. 2012 Jun;35(5):400-8. doi: 10.1097/CJI.0b013e31825898c5.

PMID:
22576345
25.

Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy.

Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, Citrin DE, Restifo NP, Robbins PF, Wunderlich JR, Morton KE, Laurencot CM, Steinberg SM, White DE, Dudley ME.

Clin Cancer Res. 2011 Jul 1;17(13):4550-7. doi: 10.1158/1078-0432.CCR-11-0116. Epub 2011 Apr 15.

26.

Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1.

Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, Wunderlich JR, Nahvi AV, Helman LJ, Mackall CL, Kammula US, Hughes MS, Restifo NP, Raffeld M, Lee CC, Levy CL, Li YF, El-Gamil M, Schwarz SL, Laurencot C, Rosenberg SA.

J Clin Oncol. 2011 Mar 1;29(7):917-24. doi: 10.1200/JCO.2010.32.2537. Epub 2011 Jan 31.

27.

Selection of CD8+PD-1+ lymphocytes in fresh human melanomas enriches for tumor-reactive T cells.

Inozume T, Hanada K, Wang QJ, Ahmadzadeh M, Wunderlich JR, Rosenberg SA, Yang JC.

J Immunother. 2010 Nov-Dec;33(9):956-64. doi: 10.1097/CJI.0b013e3181fad2b0.

28.

Tumor infiltrating lymphocyte therapy for metastatic melanoma: analysis of tumors resected for TIL.

Goff SL, Smith FO, Klapper JA, Sherry R, Wunderlich JR, Steinberg SM, White D, Rosenberg SA, Dudley ME, Yang JC.

J Immunother. 2010 Oct;33(8):840-7. doi: 10.1097/CJI.0b013e3181f05b91.

29.

CD8+ enriched "young" tumor infiltrating lymphocytes can mediate regression of metastatic melanoma.

Dudley ME, Gross CA, Langhan MM, Garcia MR, Sherry RM, Yang JC, Phan GQ, Kammula US, Hughes MS, Citrin DE, Restifo NP, Wunderlich JR, Prieto PA, Hong JJ, Langan RC, Zlott DA, Morton KE, White DE, Laurencot CM, Rosenberg SA.

Clin Cancer Res. 2010 Dec 15;16(24):6122-31. doi: 10.1158/1078-0432.CCR-10-1297. Epub 2010 Jul 28.

30.

Thoracic metastasectomy for adoptive immunotherapy of melanoma: a single-institution experience.

Klapper JA, Davis JL, Ripley RT, Smith FO, Nguyen DM, Kwong KF, Mercedes L, Kemp CD, Mathur A, White DE, Dudley ME, Wunderlich JR, Rosenberg SA, Schrump DS.

J Thorac Cardiovasc Surg. 2010 Dec;140(6):1276-82. doi: 10.1016/j.jtcvs.2010.05.020. Epub 2010 Jul 2.

31.

Enrichment of CD8+ cells from melanoma tumor-infiltrating lymphocyte cultures reveals tumor reactivity for use in adoptive cell therapy.

Prieto PA, Durflinger KH, Wunderlich JR, Rosenberg SA, Dudley ME.

J Immunother. 2010 Jun;33(5):547-56. doi: 10.1097/CJI.0b013e3181d367bd.

32.

Impact of a recombinant fowlpox vaccine on the efficacy of adoptive cell therapy with tumor infiltrating lymphocytes in a patient with metastatic melanoma.

Smith FO, Klapper JA, Wunderlich JR, Rosenberg SA, Dudley ME.

J Immunother. 2009 Oct;32(8):870-4. doi: 10.1097/CJI.0b013e3181b36b69.

33.

Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4.

Prickett TD, Agrawal NS, Wei X, Yates KE, Lin JC, Wunderlich JR, Cronin JC, Cruz P, Rosenberg SA, Samuels Y.

Nat Genet. 2009 Oct;41(10):1127-32. doi: 10.1038/ng.438. Epub 2009 Aug 30.

34.

Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen.

Johnson LA, Morgan RA, Dudley ME, Cassard L, Yang JC, Hughes MS, Kammula US, Royal RE, Sherry RM, Wunderlich JR, Lee CC, Restifo NP, Schwarz SL, Cogdill AP, Bishop RJ, Kim H, Brewer CC, Rudy SF, VanWaes C, Davis JL, Mathur A, Ripley RT, Nathan DA, Laurencot CM, Rosenberg SA.

Blood. 2009 Jul 16;114(3):535-46. doi: 10.1182/blood-2009-03-211714. Epub 2009 May 18.

35.

Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired.

Ahmadzadeh M, Johnson LA, Heemskerk B, Wunderlich JR, Dudley ME, White DE, Rosenberg SA.

Blood. 2009 Aug 20;114(8):1537-44. doi: 10.1182/blood-2008-12-195792. Epub 2009 May 7.

36.

Single-pass, closed-system rapid expansion of lymphocyte cultures for adoptive cell therapy.

Klapper JA, Thomasian AA, Smith DM, Gorgas GC, Wunderlich JR, Smith FO, Hampson BS, Rosenberg SA, Dudley ME.

J Immunol Methods. 2009 Jun 30;345(1-2):90-9. doi: 10.1016/j.jim.2009.04.009. Epub 2009 Apr 21.

37.

Analysis of the matrix metalloproteinase family reveals that MMP8 is often mutated in melanoma.

Palavalli LH, Prickett TD, Wunderlich JR, Wei X, Burrell AS, Porter-Gill P, Davis S, Wang C, Cronin JC, Agrawal NS, Lin JC, Westbroek W, Hoogstraten-Miller S, Molinolo AA, Fetsch P, Filie AC, O'Connell MP, Banister CE, Howard JD, Buckhaults P, Weeraratna AT, Brody LC, Rosenberg SA, Samuels Y.

Nat Genet. 2009 May;41(5):518-20. doi: 10.1038/ng.340. Epub 2009 Mar 29.

38.

FOXP3 expression accurately defines the population of intratumoral regulatory T cells that selectively accumulate in metastatic melanoma lesions.

Ahmadzadeh M, Felipe-Silva A, Heemskerk B, Powell DJ Jr, Wunderlich JR, Merino MJ, Rosenberg SA.

Blood. 2008 Dec 15;112(13):4953-60. doi: 10.1182/blood-2008-06-163048. Epub 2008 Sep 26.

39.

Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy.

Tran KQ, Zhou J, Durflinger KH, Langhan MM, Shelton TE, Wunderlich JR, Robbins PF, Rosenberg SA, Dudley ME.

J Immunother. 2008 Oct;31(8):742-51. doi: 10.1097/CJI.0b013e31818403d5.

40.

A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer.

Kershaw MH, Westwood JA, Parker LL, Wang G, Eshhar Z, Mavroukakis SA, White DE, Wunderlich JR, Canevari S, Rogers-Freezer L, Chen CC, Yang JC, Rosenberg SA, Hwu P.

Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6106-15.

41.

Adoptive transfer of vaccine-induced peripheral blood mononuclear cells to patients with metastatic melanoma following lymphodepletion.

Powell DJ Jr, Dudley ME, Hogan KA, Wunderlich JR, Rosenberg SA.

J Immunol. 2006 Nov 1;177(9):6527-39.

42.

Intralymphatic dendritic cell vaccination induces tumor antigen-specific, skin-homing T lymphocytes.

Grover A, Kim GJ, Lizée G, Tschoi M, Wang G, Wunderlich JR, Rosenberg SA, Hwang ST, Hwu P.

Clin Cancer Res. 2006 Oct 1;12(19):5801-8.

43.

Cancer regression in patients after transfer of genetically engineered lymphocytes.

Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, Royal RE, Topalian SL, Kammula US, Restifo NP, Zheng Z, Nahvi A, de Vries CR, Rogers-Freezer LJ, Mavroukakis SA, Rosenberg SA.

Science. 2006 Oct 6;314(5796):126-9. Epub 2006 Aug 31.

44.

De novo induction of a cancer/testis antigen by 5-aza-2'-deoxycytidine augments adoptive immunotherapy in a murine tumor model.

Guo ZS, Hong JA, Irvine KR, Chen GA, Spiess PJ, Liu Y, Zeng G, Wunderlich JR, Nguyen DM, Restifo NP, Schrump DS.

Cancer Res. 2006 Jan 15;66(2):1105-13.

45.

Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma.

Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, Royal RE, Kammula U, White DE, Mavroukakis SA, Rogers LJ, Gracia GJ, Jones SA, Mangiameli DP, Pelletier MM, Gea-Banacloche J, Robinson MR, Berman DM, Filie AC, Abati A, Rosenberg SA.

J Clin Oncol. 2005 Apr 1;23(10):2346-57.

46.

Cell transfer therapy for cancer: lessons from sequential treatments of a patient with metastatic melanoma.

Rosenberg SA, Yang JC, Robbins PF, Wunderlich JR, Hwu P, Sherry RM, Schwartzentruber DJ, Topalian SL, Restifo NP, Filie A, Chang R, Dudley ME.

J Immunother. 2003 Sep-Oct;26(5):385-93.

47.

High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens.

Morgan RA, Dudley ME, Yu YY, Zheng Z, Robbins PF, Theoret MR, Wunderlich JR, Hughes MS, Restifo NP, Rosenberg SA.

J Immunol. 2003 Sep 15;171(6):3287-95.

48.

Recombinant fowlpox viruses encoding the anchor-modified gp100 melanoma antigen can generate antitumor immune responses in patients with metastatic melanoma.

Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Topalian SL, Sherry RM, Restifo NP, Wunderlich JR, Seipp CA, Rogers-Freezer L, Morton KE, Mavroukakis SA, Gritz L, Panicali DL, White DE.

Clin Cancer Res. 2003 Aug 1;9(8):2973-80.

49.

Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients.

Dudley ME, Wunderlich JR, Shelton TE, Even J, Rosenberg SA.

J Immunother. 2003 Jul-Aug;26(4):332-42.

50.

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes.

Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry R, Restifo NP, Hubicki AM, Robinson MR, Raffeld M, Duray P, Seipp CA, Rogers-Freezer L, Morton KE, Mavroukakis SA, White DE, Rosenberg SA.

Science. 2002 Oct 25;298(5594):850-4. Epub 2002 Sep 19.

Supplemental Content

Loading ...
Support Center